Cork, M., D. Tha?i, L. Eichenfield, P. Arkwright, Z. Chen, M. Kamal, J. O’Malley, and A. Bansal. “Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years With Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and Then in a Subsequent Phase 3 Open-Label Extension Study”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s104, doi:10.25251/skin.4.supp.104.